SCHEMBL4886070

SCHEMBL4886070

O=C(O)Cn1c(C(F)(F)F)nc2ccccc21

nearest known ligand 0.77

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 4/20 0.77
CYP2C19 P33261 3/20 0.77
CYP1A2 P05177 2/20 0.77
CYP2D6 P10635 1/20 0.77
CYP3A4 P08684 1/20 0.67
MEN1 O00255 1/20 0.66
KMT2A Q03164 1/20 0.66
MAPT P10636 2/20 0.63
LMNA P02545 3/20 0.60
KDM4E B2RXH2 1/20 0.60
HSD17B10 Q99714 1/20 0.60
APEX1 P27695 2/20 0.59
ALDH1A1 P00352 2/20 0.59
TP53 P04637 1/20 0.58
HTT P42858 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
TSHR P16473 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5422578 0.87 CYP2C9 (0.71) CYP2C9CYP2C19CYP1A2CYP2D6CYP3A4
Potassium Ion SCHEMBL20299685 0.85 CYP2C9 (0.69) CYP2C9CYP2C19CYP1A2CYP2D6CYP3A4
SCHEMBL3968510 0.81 CYP2C9 (0.62) CYP2C9CYP2C19CYP1A2CYP2D6CYP3A4
SCHEMBL12968163 0.78 CYP2C9 (0.59) CYP2C9CYP2C19CYP1A2CYP2D6CYP3A4
SCHEMBL4048200 0.78 CYP2C9 (0.63) CYP2C9CYP2C19CYP1A2CYP2D6CYP3A4
SCHEMBL8599093 0.78 MAPT (0.75) CYP2C9CYP2C19CYP1A2CYP2D6CYP3A4
SCHEMBL12203802 0.78 LMNA (0.59) CYP2C9CYP2C19CYP1A2CYP2D6CYP3A4
SCHEMBL20299599 0.77 ACSS2 (0.53) CYP2C9CYP2C19CYP1A2CYP2D6APEX1
SCHEMBL14487559 0.77 CYP2C9 (0.49) CYP2C9CYP2C19CYP1A2CYP2D6CYP3A4
SCHEMBL21809123 0.77 CYP2C9 (0.58) CYP2C9CYP2C19CYP1A2CYP2D6CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3558980-B1 COMPOUNDS FOR USE IN THE TREATMENT OF KINETOPLASTID INFECTION C N C C S S C A R L COLLEZIONE NAZ DEI COMPOSTI CHIMICI E CENTRO SCREENING (IT) 2021-01-27 EP disclosed
US-10815222-B2 Compounds for use in the treatment of kinetoplastid infection C.N.C.C.S. S.C.A.R.L. COLLEZIONE NAZIONALE DEI COMPOSTI CHIMICI E CENTRO SCREENING (IT) 2020-10-27 US disclosed
US-10815222-B2 Compounds for use in the treatment of kinetoplastid infection C.N.C.C.S. S.C.A.R.L. COLLEZIONE NAZIONALE DEI COMPOSTI CHIMICI E CENTRO SCREENING (IT) 2020-10-27 US disclosed
US-20200095232-A1 COMPOUNDS FOR USE IN THE TREATMENT OF KINETOPLASTID INFECTION C.N.C.C.S. S.C.A.R.L. COLLEZIONE NAZIONALE DEI COMPOSTI CHIMICI E CENTRO SCREENING (IT) 2020-03-26 US disclosed
US-20200095232-A1 COMPOUNDS FOR USE IN THE TREATMENT OF KINETOPLASTID INFECTION C.N.C.C.S. S.C.A.R.L. COLLEZIONE NAZIONALE DEI COMPOSTI CHIMICI E CENTRO SCREENING (IT) 2020-03-26 US disclosed
EP-3558980-A1 COMPOUNDS FOR USE IN THE TREATMENT OF KINETOPLASTID INFECTION C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening (IT) 2019-10-30 EP disclosed
WO-2018115275-A1 COMPOUNDS FOR USE IN THE TREATMENT OF KINETOPLASTID INFECTION IRBM SCIENCE PARK S.P.A. (IT) 2018-06-28 WO disclosed
US-8754107-B2 Aminopyrrolidines as chemokine receptor antagonists ABBVIE INC. (US) 2014-06-17 US disclosed
US-20080176883-A1 Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone ABBVIE INC. 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176883-A1 Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone MIF, CCL5, CCR2 CYP2C9 1750/4885CYP2C19 933/4885CYP1A2 834/4885
US-10815222-B2 Compounds for use in the treatment of kinetoplastid infection NISCH, TK2, FDPS CYP2C9 2501/4885CYP2C19 1090/4885CYP1A2 941/4885
US-20200095232-A1 COMPOUNDS FOR USE IN THE TREATMENT OF KINETOPLASTID INFECTION NISCH, TK2, FDPS CYP2C9 2501/4885CYP2C19 1090/4885CYP1A2 941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.